Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02655458
Other study ID # GCO 15-1275
Secondary ID
Status Completed
Phase Phase 1
First received January 12, 2016
Last updated August 15, 2017
Start date January 2016
Est. completion date July 13, 2017

Study information

Verified date August 2017
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to explore the combination of Elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance to see what side effects it may have and how well it works for the treatment of symptomatic multiple myeloma diagnosed and treated with induction therapy in the past year.

Induction therapy is the first phase of treatment for multiple myeloma. The goal of induction therapy for multiple myeloma is to reduce the number of plasma cells in the bone marrow and the proteins that the plasma cells produce. Induction therapy is usually given for 3-4 weeks.

An autologous peripheral blood stem cell transplant is a procedure in which immature "stem cells" are collected and stored for future use. A high dose of chemotherapy is given to the patient to destroy myeloma cells, and the patient's stem cells are replaced.

The investigational drug in this program is elotuzumab. Elotuzumab is known as BMS-901608. Elotuzumab is a manufactured protein directed against a target found on multiple myeloma cells. Lenalidomide is currently approved for patients with multiple myeloma. Melphalan and cyclophosphamide, the drugs used during stem cell collection and transplant, are also approved by the U.S. FDA. Melphalan is an FDA-approved chemotherapy for multiple myeloma and is used as high-dose treatment prior to stem cell transplantation. Cyclophosphamide is an FDA-approved chemotherapy that may be used, either alone, or in combination with other drugs to treat multiple myeloma.


Description:

This is a Phase 1b, open-label, trial investigating elotuzumab and autologous PBMC reconstitution with auto-SCT consolidation therapy and lenalidomide maintenance. Fifteen patients will be enrolled in this study.

This study is based on the hypothesis that the addition of Elotuzumab and autologous PBMC reconstitution to standard-of-care auto-SCT and lenalidomide maintenance will be safe and feasible. Furthermore, we hypothesize that Elotuzumab and PBMC reconstitution will target residual myeloma cells, enhance NK cell activation and ADCC, and promote tumor-specific humoral and cellular immune responses against myeloma cells, resulting in long-term maintenance of the minimal residual disease state.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date July 13, 2017
Est. primary completion date July 13, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subject is, in the investigator's opinion, willing and able to comply with the protocol requirements.

- Subject has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to their future medical care.

Target Population

- Subjects with symptomatic MM by IMWG criteria who are receiving or have completed induction chemotherapy, who have achieved at least a PR on most recent therapy by IMWG criteria, and are eligible for auto-SCT for consolidation. A specific induction regimen is not dictated for this protocol, however, the induction regimen must not have contained melphalan (L-PAM, Alkeran).

- Age > 18 years or legal age of consent per local regulations.

- Eastern Cooperative Oncology Group (ECOG) performance status = 2.

- Documented evidence of newly diagnosed, symptomatic MM, by IMWG criteria within one year of enrollment

- Prior lenalidomide exposure is permitted only if the subject did not discontinue lenalidomide due to a related, grade = 3 AE. Age and Reproductive Status

- Men and women of childbearing potential (WOCBP) must be using 2 reliable methods of contraception to avoid pregnancy throughout the study for a period of at least 30 days before and 90 days after the last dose of investigational product in such a manner that the risk of pregnancy is minimized. See Section 4.3.3 for the definition of WOCBP and also refer to the Revlimid Risk Management Plan guidelines.

- WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG). The first should be performed within 10 to 14 days and the second within 24 hours prior to the start of the study drug. A prescription for lenalidomide for a female of childbearing potential must not be issued by the prescriber until negative pregnancy tests have been verified by the prescriber.

- Women must not be breastfeeding.

- Men must agree to use a latex condom and a second form of birth control during sexual contact with WOCBP, even if they have had a successful vasectomy, and must agree not to donate sperm during study drug therapy and for 90 days after therapy.

- Subjects must be willing to refrain from blood donations during study drug therapy and for 8 weeks after therapy.

Exclusion Criteria:

Target Disease

- MGUS, Waldenström's macroglobulinemia, or asymptomatic (smoldering) myeloma.

- Active plasma cell leukemia (defined as either 20% of peripheral white blood cells comprised of plasma/CD138+ cells or an absolute plasma cell count of 2 x 109/L).

Medical History and Concurrent Diseases

- All AEs of any prior chemotherapy, surgery, or radiotherapy not resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v.4.0) Grade = 2.

- POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).

- Acute renal failure due solely to readily reversible causes such as hypercalcemia, hyperuricemia, dehydration, hyperviscosity, or acute tubular necrosis from nephrotoxic drugs.

- Significant cardiac disease as determined by the investigator including:

1. Known or suspected cardiac amyloidosis

2. Congestive heart failure of Class III or IV of the NYHA classification

3. Uncontrolled angina, hypertension or arrhythmia

4. Myocardial infarction in the past 6 months

5. Any uncontrolled or severe cardiovascular disease

- Prior cerebrovascular event with persistent neurologic deficit.

- Known HIV Infection or active hepatitis A, B or C.

- Any medical conditions that, in the investigator's opinion, would impose excessive risk to the subject.

Examples of such conditions include:

a. Any uncontrolled disease, such as pulmonary disease, infection, seizure disorder b. Any altered mental status or any psychiatric condition that would interfere with the understanding of the informed consent c. Active infection that requires parenteral anti-microbial or anti-parasitic treatment

- Prior or concurrent malignancy, except for the following:

1. Adequately treated basal cell or squamous cell skin cancer;

2. Or any other cancer from which the subject has been disease-free for > 5 years

- Uncontrolled diabetes (defined as Hgb A1C > 8.0%)

- Unable to tolerate thromboembolic prophylaxis including, as clinically indicated, aspirin, Coumadin (warfarin) or dose adjusted low-molecular weight heparin. Physical and Laboratory Test Findings

- Corrected serum calcium > 11.5 mg/dl within 2 weeks of enrollment.

- Absolute neutrophil count < 1000 cells/mm3. No granulocyte colony stimulating factors (G-CSF or GMCSF) allowed within 1 week of enrollment. No pegylated granulocyte colony stimulating factors are allowed within 3 weeks of treatment start.

- Platelets < 75,000 cell/mm3 (75 x 109/L). Qualifying laboratory value must occur at most recent measurement before enrollment and must be no more than 14 days before enrollment. No transfusions are allowed within 72 hours before qualifying laboratory value.

- Hemoglobin < 8 g/dL. Qualifying laboratory value must occur at most recent measurement before enrollment and must be no more than 14 days before enrollment. No transfusions are allowed within 72 hours before qualifying laboratory value.

- Total bilirubin > 2X ULN ,or direct bilirubin > 2.0 mg/dL.(except patients with Gilbert's syndrome then total bilirubin >2X ULN allowed in the absence of other hepatic signs or symptoms)

- AST or ALT > 3X ULN.

- CrCl < 60 ml/min by Cockcroft-Gault Formula Prior Therapy or Surgery

- Major surgery within 3 weeks prior to treatment.

- Kyphoplasty or vertebroplasty within 1 week of enrollment.

- Prior allogeneic stem cell transplant

- Treatment with plasmapheresis within 4 weeks before enrollment.

- Prior therapy with elotuzumab or any IMiD (including pomalidomide), except for prior thalidomide or lenalidomide (as defined in inclusion criteria).

- NSAIDs, IV contrast, aminoglycosides, or other potentially nephrotoxic drugs within 2 weeks of enrollment.

- Steroids within 3 weeks of enrollment, except:

1. = 10 mg prednisone or equivalent per day

2. Steroid with little to no systemic absorption (ie, topical or inhaled steroids) Allergies and Adverse Drug Reaction

- Known hypersensitivity to lenalidomide, dexamethasone, any excipients in the elotuzumab formulation (sodium citrate, citric acid, sucrose and polysorbate 80) or recombinant protein.

- History of Grade 4 rash associated with thalidomide treatment. Sex and Reproductive Status

- Women of childbearing potential (WOCBP) who are pregnant or lactating or unwilling to use 2 forms of effective birth control.

- Men who are fertile and sexually active unwilling to use 2 forms of effective birth control if their partners are WOCBP. Other Exclusion Criteria

- Prisoners or subjects who are involuntarily incarcerated.

- Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Elotuzumab
The following must also be administered before any elotuzumab: Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po).
Lenalidomide
On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
Other:
autologous PBMC reconstitution
Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.
ASCT
Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are "harvested," stored and then returned to the body (engrafted). To be done as part of standard of care.

Locations

Country Name City State
United States Icahn School of Medicine at Mount Sinai New York New York

Sponsors (2)

Lead Sponsor Collaborator
Hearn Jay Cho Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of completion of treatment Safety and tolerability will be measured by the number of evaluable patients who complete the treatment protocol. up to 24 months
Secondary IFE level Immunofixation Serum Test (IFE) level up to 24 months
Secondary sFLC level Serum Free Light Chain analysis (sFLC) level up to 24 months
Secondary Bone marrow MRD analysis Bone marrow disease (MRD) is the name for small numbers of leukaemic cells in the bone marrow up to 24 months
Secondary Progression-Free Survival number of participants at 24 months who are progression-free up to 24 months
Secondary CyTOF mass cytometry Immune cell reconstitution will be assessed by Cytometry by Time-Of-Flight (CyTOF) mass cytometry. This method quantifies and characterizes all cellular immune compartments. up to 24 months
Secondary SPEP level Serum protein electrophoresis (SPEP) level up to 24 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1